Limits...
Pharmaceutical pricing, cost containment and new treatments for rare diseases in children.

Stella P, Gold-von Simson G - Orphanet J Rare Dis (2014)

Bottom Line: Cost-containment in healthcare spending has become a central issue in public policy and healthcare reform, especially as the affordable care act adds millions of people to public and private insurance rolls.In this climate, longstanding criticism of pharmaceutical pricing has grown sharper, and many in both policy and medicine have characterized the costs of newly developed drugs as both exorbitant and wasteful of scarce healthcare resources.At the same time, pharmaceutical research and development pipeline costs are increasing exponentially.

View Article: PubMed Central - PubMed

ABSTRACT
Cost-containment in healthcare spending has become a central issue in public policy and healthcare reform, especially as the affordable care act adds millions of people to public and private insurance rolls. In this climate, longstanding criticism of pharmaceutical pricing has grown sharper, and many in both policy and medicine have characterized the costs of newly developed drugs as both exorbitant and wasteful of scarce healthcare resources. At the same time, pharmaceutical research and development pipeline costs are increasing exponentially.

Show MeSH

Related in: MedlinePlus

Recent drug approvals, volumes, and prices. (a. Trajectory of FDA Approval for Orphan Drugs, 1984-2012 [11]. b. Recent trends in pharmaceutical revenue, pricing and volume) [1].
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4221662&req=5

Fig1: Recent drug approvals, volumes, and prices. (a. Trajectory of FDA Approval for Orphan Drugs, 1984-2012 [11]. b. Recent trends in pharmaceutical revenue, pricing and volume) [1].

Mentions: Although total sales of pharmaceuticals in the United States were essentially flat from 2007 to 2012, this stable revenue conceals a marked shift in the industry, as drug companies have increasingly benefited from aggressive pricing despite declining volumes of drugs sold [1]. (FigureĀ 1) This trend has many plausible causes, from routine changes in portfolio composition due to patent expirations of particularly successful mass market drugs, to evolving healthcare delivery and payment systems, and even fundamental improvements in basic science and biotechnology. But whatever the cause, this trend has significant political and public health implications, and therefore is of serious concern to those who discover, develop, manufacture, or recommend the use of very high cost drugs.Figure 1


Pharmaceutical pricing, cost containment and new treatments for rare diseases in children.

Stella P, Gold-von Simson G - Orphanet J Rare Dis (2014)

Recent drug approvals, volumes, and prices. (a. Trajectory of FDA Approval for Orphan Drugs, 1984-2012 [11]. b. Recent trends in pharmaceutical revenue, pricing and volume) [1].
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4221662&req=5

Fig1: Recent drug approvals, volumes, and prices. (a. Trajectory of FDA Approval for Orphan Drugs, 1984-2012 [11]. b. Recent trends in pharmaceutical revenue, pricing and volume) [1].
Mentions: Although total sales of pharmaceuticals in the United States were essentially flat from 2007 to 2012, this stable revenue conceals a marked shift in the industry, as drug companies have increasingly benefited from aggressive pricing despite declining volumes of drugs sold [1]. (FigureĀ 1) This trend has many plausible causes, from routine changes in portfolio composition due to patent expirations of particularly successful mass market drugs, to evolving healthcare delivery and payment systems, and even fundamental improvements in basic science and biotechnology. But whatever the cause, this trend has significant political and public health implications, and therefore is of serious concern to those who discover, develop, manufacture, or recommend the use of very high cost drugs.Figure 1

Bottom Line: Cost-containment in healthcare spending has become a central issue in public policy and healthcare reform, especially as the affordable care act adds millions of people to public and private insurance rolls.In this climate, longstanding criticism of pharmaceutical pricing has grown sharper, and many in both policy and medicine have characterized the costs of newly developed drugs as both exorbitant and wasteful of scarce healthcare resources.At the same time, pharmaceutical research and development pipeline costs are increasing exponentially.

View Article: PubMed Central - PubMed

ABSTRACT
Cost-containment in healthcare spending has become a central issue in public policy and healthcare reform, especially as the affordable care act adds millions of people to public and private insurance rolls. In this climate, longstanding criticism of pharmaceutical pricing has grown sharper, and many in both policy and medicine have characterized the costs of newly developed drugs as both exorbitant and wasteful of scarce healthcare resources. At the same time, pharmaceutical research and development pipeline costs are increasing exponentially.

Show MeSH
Related in: MedlinePlus